No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 9 of the 32 quarters in the window, leaving 23 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 12.8x · 10Y median 8044.1x · 8th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 34
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:06:55.088Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA and cash-flow multiples are withheld until their applicability to this financial-services business is verified. The lenses that apply are shown above; see also P/B and ROE.
The latest delayed quote for Solana Company (HSDT) stock was $2.65 as of Oct 6, 2026, 10:05 AM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months -83.2% · 3-year avg -92.5%/yr · 5-year avg -91.3%/yr
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness.
Asset Management · Newtown, PA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 17, 2026
42 days away
EPS Estimate
0.02
Revenue Est.
$2.85M
Last Quarter Results
EPS
$-0.03
vs Estimate
$-0.02
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1HSDT | $154.72M | $2.65 | +0.00% | -83.19% | -91.26% | -77.21% | N/A |
| 2INAC | $153.45M | $10.40 | +0.10% | +4.30% | N/A | N/A | vs HSDT |
| 3CCAQ | $153.01M | $10.56 | +0.71% | +3.74% | N/A | N/A | vs HSDT |
| 4FINW | $150.77M | $11.00 | -0.18% | -40.09% | N/A | N/A | vs HSDT |
| 5IDAC | $158.84M | $9.99 | N/A | N/A | N/A | N/A | vs HSDT |
| 6FMAC | $158.93M | $10.07 | -0.28% | N/A | N/A | N/A | vs HSDT |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$2.53M
vs Estimate
$3.50M
Consensus Rating
Based on 2 analysts
Average Price Target
$3.50
+32.1% upside
Low
$3.00
Current
$2.65
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Quarter ending Dec 2026 | $-0.01 | $-0.01 | $0.00 | 1 |
| Quarter ending Mar 2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Quarter ending Jun 2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.79 | $-1.64 | $-1.49 | 1 |
| FY 2027 | $0.01 | $0.01 | $0.01 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.60M | $2.85M | $3.10M | 1 |
| Quarter ending Dec 2026 | $3.05M | $3.35M | $3.65M | 1 |
| Quarter ending Mar 2027 | $3.10M | $3.40M | $3.70M | 1 |
| Quarter ending Jun 2027 | $3.14M | $3.45M | $3.76M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $11.40M | $12.25M | $13.10M | 1 |
| FY 2027 | $12.89M | $13.85M | $14.81M | 1 |
